BS01 / Bionic Sight, Beacon Therapeutics - LARVOL DELTA

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Bionic Sight LLC

New P1/2 trial • Age-related Macular Degeneration • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

BS01 in Patients With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=20 | Active, not recruiting | Sponsor: Bionic Sight LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

BS01 in Patients With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Bionic Sight LLC | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

Bionic Sight’s BS01 Gene Therapy Receives RMAT Designation from the FDA (GlobeNewswire) - "Bionic Sight, Inc...announced today that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational product BS01 for the treatment of retinitis pigmentosa (RP) patients with advanced stage vision loss....The RMAT designation for BS01 was based on the preliminary data from Bionic Sight’s ongoing first-in-human Phase 1/2 clinical trial."

FDA event • Retinitis Pigmentosa

BS01 in Patients With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2 | N=20 | Recruiting | Sponsor: Bionic Sight LLC | Trial completion date: Dec 2027 ➔ Dec 2029

Trial completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

BS01 in Patients With Retinitis Pigmentosa (clinicaltrials.gov) - P1/2; N=20; Recruiting; Sponsor: Bionic Sight LLC; Trial completion date: Jun 2026 ➔ Dec 2027; Trial primary completion date: Jun 2022 ➔ Dec 2022

Clinical • Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa